Zacks
Jazz Pharmaceuticals (JAZZ) Beats Q4 Earnings and Revenue Estimates
📈
AI Sentiment
Highly Positive
8/10
- Home
- PBYI
as of 02-26-2026 9:30am EST
$7.61
$0.07
-0.91%
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | LOS ANGELES |
| Market Cap: | 263.4M | IPO Year: | 2011 |
| Target Price: | $7.00 | AVG Volume (30 days): | 370.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.35 | EPS Growth: | 37.78 |
| 52 Week Low/High: | $2.58 - $7.68 | Next Earning Date: | N/A |
| Revenue: | $27,685,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | -1.97% | Revenue Growth (next year): | -0.68% |
| P/E Ratio: | 21.94 | Index: | N/A |
| Free Cash Flow: | 38.9M | FCF Growth: | +27.27% |
Stock Insider Trading Activity of Puma Biotechnology Inc (PBYI)
NOUGUES MAXIMO F
Sell
Chief Financial Officer
PBYI Jan 7, 2026
Avg Cost/Share
$5.88
Shares
6,405
Total Value
$37,654.99
Owned After
193,284
SEC Form 4
HUNT DOUGLAS M
Sell
See Remarks
PBYI Jan 7, 2026
Avg Cost/Share
$5.88
Shares
5,014
Total Value
$29,477.31
Owned After
155,907
SEC Form 4
AUERBACH ALAN H
Sell
President and CEO
PBYI Jan 7, 2026
Avg Cost/Share
$5.88
Shares
18,012
Total Value
$105,892.55
Owned After
7,145,951
SEC Form 4
NOUGUES MAXIMO F
Sell
Chief Financial Officer
PBYI Jan 6, 2026
Avg Cost/Share
$5.84
Shares
4,540
Total Value
$26,531.76
Owned After
193,284
SEC Form 4
HUNT DOUGLAS M
Sell
See Remarks
PBYI Jan 6, 2026
Avg Cost/Share
$5.84
Shares
3,973
Total Value
$23,218.21
Owned After
155,907
SEC Form 4
AUERBACH ALAN H
Sell
President and CEO
PBYI Jan 6, 2026
Avg Cost/Share
$5.84
Shares
16,938
Total Value
$98,985.67
Owned After
7,145,951
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| NOUGUES MAXIMO F | PBYI | Chief Financial Officer | Jan 7, 2026 | Sell | $5.88 | 6,405 | $37,654.99 | 193,284 | |
| HUNT DOUGLAS M | PBYI | See Remarks | Jan 7, 2026 | Sell | $5.88 | 5,014 | $29,477.31 | 155,907 | |
| AUERBACH ALAN H | PBYI | President and CEO | Jan 7, 2026 | Sell | $5.88 | 18,012 | $105,892.55 | 7,145,951 | |
| NOUGUES MAXIMO F | PBYI | Chief Financial Officer | Jan 6, 2026 | Sell | $5.84 | 4,540 | $26,531.76 | 193,284 | |
| HUNT DOUGLAS M | PBYI | See Remarks | Jan 6, 2026 | Sell | $5.84 | 3,973 | $23,218.21 | 155,907 | |
| AUERBACH ALAN H | PBYI | President and CEO | Jan 6, 2026 | Sell | $5.84 | 16,938 | $98,985.67 | 7,145,951 |
Latest Puma Biotechnology Inc News
PBYI Breaking Stock News: Dive into PBYI Ticker-Specific Updates for Smart Investing
Compare PBYI vs Leading Stocks
See how PBYI stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PBYI Puma Biotechnology Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.